CXCL17蛋白促进顺铂诱导HepG2肝癌细胞自噬形成

doi:10.13418/j.issn.1001-165x.2019.03.009

中国临床解剖学杂志 ›› 2019, Vol. 37 ›› Issue (3) : 282-286. DOI: 10.13418/j.issn.1001-165x.2019.03.009

周志涛¹,　路艳蒙¹，　张千兵²

作者信息 +

Autophagy induces drug resistance in human hepatocellular carcinoma cells line HepG2 by increasing CXCL17 protein expression

ZHOU Zhi-tao¹, LU Yan-meng¹, ZHANG Qian-bing²

Author information +

文章历史 +

摘要

目的　探讨CXCL17调节肝癌细胞化疗耐药产生的机制。方法　构建过表达CXCL17的HepG2细胞系。实验分为过表达CXCL17组，空白质粒组以及对照组。转染的细胞提取总蛋白，Western blot检测蛋白表达状态，流式细胞仪及电镜检测药物作用后的细胞变化。结果　CXCL17过表达的HepG2细胞株较其亲代细胞对顺铂引起的细胞毒作用和凋亡敏感性下降，但是尚未完全被抑制，而细胞内的自噬增加，线粒体损伤减少，溶酶体增多。结论　CXCL17通过促进细胞自噬参与调节HepG2细胞的化疗耐药。

Abstract

Objective　To investigate the mechanism of the development of cisplatin resistance in a hepatocellular carcinoma cell line.　Methods　Over-expression of CXCL17 gene was induced in human hepatocellular carcinoma cells. Western blotting was used to investigate the protein expression of full length CXCL17. Flow cytometry and electron microscopy were used to examine the apoptotic morphological changes after cisplatin treatment in HepG2.　Results　CXCL17 over-expression cells was more resistant to cisplatin-induced cytotoxicity and apoptosis than HepG2 cells. Compared with HepG2 cells, CXCL17 over-expression cells exhibited less apoptosis and more autophagy with decreased CTR1 protein expression. Conclusion　Cisplatin induces drug resistant phenotype by decreasing the protein level of CXCL17, suggesting an autophagic response to cisplatin as a survival mechanism that can promote chemo-resistance.

导出引用

周志涛, 路艳蒙, 张千兵. CXCL17蛋白促进顺铂诱导HepG2肝癌细胞自噬形成[J]. 中国临床解剖学杂志. 2019, 37(3): 282-286 https://doi.org/10.13418/j.issn.1001-165x.2019.03.009

ZHOU Zhi-tao, LU Yan-meng, ZHANG Qian-bing. Autophagy induces drug resistance in human hepatocellular carcinoma cells line HepG2 by increasing CXCL17 protein expression[J]. Chinese Journal of Clinical Anatomy. 2019, 37(3): 282-286 https://doi.org/10.13418/j.issn.1001-165x.2019.03.009

中图分类号： R735.7

参考文献

[1] Weinstein EJ, Head R, Griggs DW, et al. VCC-1, a novel chemokine, promotes tumor growth[J]. Biochem Biophys Res Commun, 2006, 350(1): 74-81.
[2] Pisabarro MT, Leung B, Kwong M, et al. Cutting edge: novel human dendritic cell-and monocyte-attracting chemokine-like protein identified by fold recognition methods [J]. J Immunol, 2006, 176(4): 2069-2073.
[3] Zlotnik A, Yoshie O. The chemokine superfamily revisited[J]. Immunity, 2012, 36(5): 705-716.
[4] Maravillas-Montero JL, Burkhardt AM, Hevezi PA, et al. Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17[J]. J Immunol, 2015, 194(1): 29-33.
[5] 刘振生, 赵红川, 黄帆, 等. VCC-1在肝癌患者血、尿和癌组织中的表达及其意义[J]. 肝胆外科杂志, 2014, 22(6): 471-473.
[6] Burkhardt AM, Tai KP, Flores-Guiterrez JP, et al. CXCL17 is a mucosal chemokine elevated in idiopathic pulmonary fibrosis that exhibits broad antimicrobial activity[J]. J Immunol, 2012, 188(12): 6399-6406.
[7] Hernández-Ruiz M, Zlotnik A. Mucosal chemokines[J]. J Interferon Cytokine Res, 2017, 37(2): 62-70.
[8] Zhou Z, Lu X, Zhu P, et al. VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells[J]. Biochem Biophys Res Commun, 2012, 420(2): 336-342.
[9] 牟霞, 陈瑶, 王穗海, 等. VCC-1真核表达载体的构建及肝癌细胞SMMC7721稳定转染株的建立及鉴定[J]. 细胞与分子免疫学杂志, 2009, 25(1): 79-81.
[10] Lee WY, Wang CJ, Lin TY, et al. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor[J]. Am J Physiol Endocrinol Metab, 2013, 304(1): E32-40.
[11]刘祖平, 杨成万. CXCL17在肿瘤中表达意义及功能的研究进展[J]. 西南医科大学学报, 2018, 41(5): 462-466.
[12] 韩兴涛, 杨凌博, 魏澎涛, 等. miR-210-3p通过靶向ATG7抑制人膀胱癌细胞J82的自噬和诱导凋亡[J]. 中国临床解剖学杂志, 2018, 36(6): 615-620.
[13] Lorin S, Hamaï A, Mehrpour M, et al. Autophagy regulation and its role in cancer [J]. Semin Cancer Biol, 2013, 23(5): 361-379.
[14] 胡晓芳, 邱仁杰, 余磊, 等. 纳米载体SWCNT投递Bcl-2 siRNA促进U251细胞凋亡[J]. 中国临床解剖学杂志, 2017, 35(05): 521-525.